Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 7248Neoplasms 4547Prostatic Neoplasms 3494Colorectal Neoplasms 2941Carcinoma, Non-Small-Cell Lung 2832Lung Neoplasms 2548Leukemia, Myeloid, Acute 1983Pancreatic Neoplasms 1875Multiple Myeloma 1812Carcinoma, Hepatocellular 1735Neoplasm Metastasis 1587Stomach Neoplasms 1502Lymphoma 1457Head and Neck Neoplasms 1437Precursor Cell Lymphoblastic Leukemia-Lymphoma 1435Brain Neoplasms 1374Melanoma 1349Ovarian Neoplasms 1347Leukemia 1303Rectal Neoplasms 1270Recurrence 1255Colonic Neoplasms 1204Glioblastoma 1140Uterine Cervical Neoplasms 1098Lymphoma, Non-Hodgkin 1066Leukemia, Lymphocytic, Chronic, B-Cell 989Esophageal Neoplasms 965Lymphoma, Follicular 938Lymphoma, Large B-Cell, Diffuse 933Squamous Cell Carcinoma of Head and Neck 921

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Interventional × Metastatic Hormone Refractory Prostate Cancer × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡